热门资讯> 正文
2022-01-04 11:36
10:30 PM EST, 01/03/2022 (MT Newswires) -- Alphamab Oncology (HKG:9966) unit Jiangsu Alphamab Biopharmaceuticals renewed a property and equipment lease agreement with biologics manufacturer Suzhou Alphamab for another two years from Jan. 1, 2022 to March 31, 2024, according to a late Monday filing.
The new deal comes as the lease agreement secured in 2019 expired on Dec. 31, 2021.
Jiangsu Alphamab will pay Suzhou a rental fee of 838,900 yuan ($132,000) per month to lease the 2,235-square-meter premises of a building in China's Jiangsu province, used for biologics manufacturing and relevant materials storage.
The drugmaker said the lease amount will be settled on a quarterly basis.
Shares fell over 5% recently.